Showing 2,392 news articles about HIV treatment

Filters Content type: Editors' picks Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

Injectable & long-acting HIV treatment

DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product

Editor's pick
DURECT press release
6 August 2019
Resistance

Alarming surge in drug-resistant HIV uncovered

Editor's pick
Nature
3 August 2019
Changing treatment

High efficacy from switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance

Editor's pick
i-Base
2 August 2019
People with limited treatment options

Clinical and Economic Effects of Ibalizumab for Multidrug-Resistant HIV

Editor's pick
Infectious Disease Advisor
2 August 2019
Injectable & long-acting HIV treatment

ViiV Healthcare submits regulatory application to EMA for the first monthly, injectable treatment for HIV

Editor's pick
ViiV press release
30 July 2019
People with limited treatment options

EMA panel recommends ibalizumab for multidrug-resistant HIV-1

Editor's pick
Medscape (requires free registration)
30 July 2019
Treatment for women

What’s in a pill? Promise, uncertainty, rands, lives & loves … but rights? What the next big thing in HIV treatment for SA shows us

Editor's pick
Bhekisisa
29 July 2019
Changing treatment

Biktarvy Suppresses HIV Well in Women and Those With Drug Resistance

Editor's pick
POZ
29 July 2019
Starting treatment

Africa: What are we to make of the ADVANCE trial results?

Editor's pick
Spotlight
25 July 2019
Child developmental issues

Folic acid reduces risk of defects linked to dolutegravir

Editor's pick
Baylor College of Medicine
25 July 2019
Pharmaceutical industry

Can new Dovato data jump-start uptake of 2-drug HIV regimen? ViiV hopes so

Editor's pick
FiercePharma
24 July 2019
Resistance

WHO: Pretreatment HIV drug resistance exceeds 10% in many places

Editor's pick
Healio
24 July 2019
People with limited treatment options

AIDS Conference Returns to Mexico City, Where We Saw an Underrated, Great Advance in HIV Therapy

Editor's pick
NEJM Journal Watch
24 July 2019
New & experimental HIV treatments

2019 Pipeline Report

Editor's pick
TAG
23 July 2019
Women

The New Face of HIV and Treating the 'Hardly Reached'

Editor's pick
Medscape (requires free registration)
20 July 2019
Retention & linkage to care

Adults with HIV who have compassionate care providers start and remain in treatment longer

Editor's pick
ScienceDaily
15 July 2019
Injectable & long-acting HIV treatment

ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice

Editor's pick
ViiV Healthcare press release
11 July 2019
Kidney problems

Analysis Backs New Tenofovir’s Kidney Safety Over Old Version

Editor's pick
POZ
11 July 2019
Pharmaceutical industry

GSK touts new Dovato switching data. Is it enough to shake Gilead's HIV lead?

Editor's pick
FiercePharma
11 July 2019
Injectable & long-acting HIV treatment

Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics

Editor's pick
Lyndra Therapeutics press release
10 July 2019
Transgender people

What the Trans Community Needs to Know About New Expert Recommendations

Editor's pick
The Body
8 July 2019
Changing treatment

Drug-Resistance Mutations May Curb Efficacy of Dolutegravir-Based Regimens in Zimbabwe Teens With HIV

Editor's pick
Medscape (free registration required)
7 July 2019
Global health targets

WHO’s “Treat All” Policy Had Immediate Effect on Global HIV Treatment Rates

Editor's pick
POZ
4 July 2019
New & experimental HIV treatments

ViiV Healthcare receives EU marketing authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection

Editor's pick
ViiV press release
3 July 2019